Ethics

Ethics & Compliance Reviewer

SCORE: 5 CONFIDENCE: 5

Summary

This manuscript presents a complete and well-executed study identifying IPO9 as a regulator of cGAS-STING signaling through a phenotypic screening campaign. The work is ethically sound with appropriate disclosures. All required compliance statements are present and properly documented.

Ethics & Compliance Assessment

Animal research: The manuscript describes in vivo studies in wild-type and Trex1−/− C57BL/6J mice (Methods: "cGAMP Measurement in In Vivo Trex1 knockout mice"). No IACUC approval number or institutional animal care committee statement is provided in the text. This is a HARD gap: the authors state mice were "a gift from the Stetson lab" and describe dosing and tissue harvest procedures, but do not name the approval body or protocol number.

Human subjects and identifiable data: The manuscript uses peripheral blood mononuclear cells (PBMCs) from "healthy volunteers and given as a gift from the Teijaro Lab at Scripps Research" (Methods: Cell Culture). No IRB approval, informed consent statement, or de-identification procedure is documented. This is a HARD gap: human biological material is used, but no consent or exemption statement appears.

Competing interests: A patent application is declared: "Small molecule inhibitors of cyclic GMP-AMP synthase (cGAS)" (Competing Interest Declaration, U.S. Patent Application 63/203,219). This is properly disclosed.

Funding: No funding sources are explicitly stated in the manuscript. The Acknowledgements section thanks CIRM (California Institute for Regenerative Medicine) for support to A.S. (EDUC4-12811), but no broader funding statement appears in a dedicated section. This is a SOFT gap: partial disclosure is present but incomplete.

Dual-use or biosafety risk: The work involves small-molecule inhibitors of an innate immune pathway but does not present biosafety concerns on its face. No dual-use risk is apparent.

---

Specific Findings

HARD: Animal protocol approval. The manuscript describes in vivo dosing and tissue harvest in mice but provides no IACUC approval number, committee name, or protocol identifier. Provide the approval reference or confirm exemption status.

HARD: Human subject consent. PBMC experiments use human biological material without a documented consent statement, IRB approval number, or exemption justification. Provide the IRB approval reference, consent mechanism, or exemption basis.

SOFT: Funding disclosure. CIRM funding is acknowledged for one author but no comprehensive funding statement is present. A complete funding disclosure section would improve transparency.